Antibody–drug conjugates (ADCs) have transformed oncology by combining the specificity of monoclonal antibodies with the potent cytotoxicity of small molecules. With multiple approvals in hematologic malignancies and solid tumors, ADCs have redefined therapeutic strategies. However, the complex structure and dual nature of ADCs-comprising antibody, linker, and payload-create unique challenges in preclinical-to-clinical translation.
At Prisys Biotech, we provide a comprehensive PK/PD translational research framework, ensuring robust characterization of ADC behavior in vivo, supporting dose selection, and enhancing clinical predictability.
Key Challenges in ADC Development
Complex Pharmacokinetics
ADC pharmacokinetics are influenced by antibody stability, linker chemistry, payload physicochemical properties, and in vivo deconjugation. This results in multiple analytes requiring parallel monitoring-conjugated drug, total antibody, and free payload.
Safety and Toxicity Risks
ADC safety is shaped not only by pharmacological activity but also by off-target effects, biophysical properties, and immunogenicity risks. Hematological toxicities such as thrombocytopenia and neutropenia are particularly important for translational evaluation.
PK/PD Relationship
ADC efficacy depends on achieving sufficient target-site exposure while limiting systemic toxicity. Quantitative PK/PD modeling is essential for linking drug concentration with pharmacological response and predicting human outcomes.
Immunogenicity Considerations
Anti-drug antibody (ADA) formation can alter clearance, distribution, and efficacy, requiring careful monitoring during preclinical assessment.
Translational PK/PD Framework for ADCs
Prisys Biotech integrates non-human primate (NHP) models, advanced bioanalytical methods, and computational modeling into a unified framework:
Bioanalytical Characterization
Use of affinity capture LC-MS/MS to monitor DAR (drug-to-antibody ratio) distribution, linker stability, and payload release, providing mechanistic insights into in vivo drug modification.
Species Selection and Scaling
NHPs remain the most relevant model for ADC PK scaling to humans. While simple allometric scaling is often adequate for antibody-dominated kinetics, linker and payload chemistry may introduce variability requiring refinement.
FIH Dose Estimation
First-in-human (FIH) dose design typically integrates both large-molecule approaches (HNSTD, NOAEL) and small-molecule metrics (STD10, BSA scaling), applying conservative safety factors for novel payloads.
Efficacy Dose Prediction
From empirical body-weight–based extrapolation to semi-mechanistic tumor growth inhibition models and advanced multiscale quantitative systems pharmacology (QSP) frameworks, modeling guides effective dose selection and regimen optimization.
Safety Translation
Hematological toxicities are modeled across species, incorporating protein-binding differences and marrow sensitivity. Data from NHP studies are used to refine human risk prediction and inform mitigation strategies.
Why Prisys Biotech?
Expertise in NHP Pharmacology: Extensive experience in cynomolgus monkey PK/PD studies ensures translational relevance for ADC programs.
Integrated Bioanalysis: Advanced analytical platforms capable of quantifying conjugated, total antibody, and free payload with high sensitivity.
Modeling and Simulation: Application of semi-mechanistic and mechanistic PK/PD models to predict human dosing, efficacy, and safety.
Comprehensive Safety Evaluation: Specialized expertise in hematological toxicity assessment and immunogenicity risk analysis.
Clinical Translation Focus: Direct alignment of preclinical findings with regulatory expectations for IND-enabling studies.
Conclusion
ADC development demands a multidisciplinary translational strategy that integrates pharmacology, safety, and advanced modeling. At Prisys Biotech, we provide the tools and expertise to overcome the complexity of ADC research-delivering reliable PK/PD data, predictive modeling, and NHP-based translational insights. By bridging preclinical findings with clinical outcomes, Prisys empowers pharmaceutical partners to accelerate ADC innovation and optimize therapeutic success.
